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Abstract 
Sarcopenia and frailty are geriatric syndromes characterised by multi-system decline, which 
are related to and reflected by markers of skeletal muscle dysfunction. In older people 
sarcopenia and frailty have been used for risk stratification, to predict adverse outcomes, 
and to prompt intervention aimed at preventing decline in those at greatest risk. In this 
review we examine sarcopenia and frailty in the context of chronic respiratory disease, 
providing an overview of the common assessments tools and studies to date in the field. We 
contrast assessments of sarcopenia, which consider muscle mass and function, with 
assessments of frailty, which often additionally consider social, cognitive and psychological 
domains. Frailty is emerging as an important syndrome in respiratory disease, being strongly 
associated with poor outcome. We also unpick the relationship between sarcopenia, frailty 
and skeletal muscle dysfunction in chronic respiratory disease and reveal these as 
interlinked but distinct clinical phenotypes. Suggested areas for future work include the 
application of sarcopenia and frailty models to restrictive diseases and population-based 
samples, prospective prognostic assessments of sarcopenia and frailty in relation to 
common multidimensional indices, plus the investigation of exercise, nutritional and 
pharmacological strategies to prevent or treat sarcopenia and frailty in chronic respiratory 
disease. 
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Introduction 
Skeletal muscle dysfunction is a well-recognised manifestation of chronic respiratory disease 
(1, 2). Among people with chronic obstructive pulmonary disease (COPD) for example, 
common changes in the muscular system include quadriceps weakness (3), atrophy (4), and 
a fibre type shift (5), each of which offers prognostic information independent of lung 
function (6-8). One mechanism through which skeletal muscle dysfunction may contribute 
to poor outcome is by precipitating so called ‘geriatric syndromes’- age-related 
multifactorial health conditions (9) - most notably sarcopenia and frailty. 
Sarcopenia describes the loss of skeletal muscle and associated decline in physical function 
(10), a diagnosis of which under current international consensus requires a marker of low 
muscle mass and reduced muscular/physical performance (11). Frailty overlaps with 
sarcopenia, though describes a broader syndrome characterized by vulnerability and a 
heightened state of risk following minor stressor events (12). Skeletal muscle dysfunction is 
often considered within common diagnostic criteria for frailty, via muscle weakness and a 
positive weight loss history that is often the product of muscle wasting (12, 13). As well as 
reflecting skeletal muscle dysfunction both syndromes consider wider impacts of disease, 
from within and beyond the lungs, which influence morbidity and mortality (14). The 
presence of sarcopenia or frailty can therefore be considered a ‘vital sign’ and provides 
prognostic information further to that offered by markers of skeletal muscle dysfunction 
alone. 
In older people, sarcopenia and frailty have proved to be useful tools for risk stratification, 
prognostication, and to direct interventions aimed at preventing functional decline towards 
those carrying the greatest risk. Both are consistently associated with increased risk of 
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incident disability, falls, hospitalization and mortality (12, 15-20). Early intervention with 
exercise or nutrition can help reduce this risk, and both syndromes can be effectively 
managed, in some cases reversed, thus benefitting older people and their families plus 
reducing dependence on health and social care services. These syndromes have only 
recently been applied to groups with chronic respiratory disease. However, early findings 
have sparked interest in the field, particularly those relating to frailty which appears highly 
prevalent (16), a strong predictor of poor outcome (21), and provides important information 
for care planning, e.g. in relation to lung transplant listing (19). 
In this review we consider sarcopenia and frailty syndromes in the context of chronic 
respiratory disease. We provide an overview of the common approaches and assessment of 
these syndromes from gerontology, summarize studies examining sarcopenia and frailty in 
people with chronic respiratory disease, and explore the relationships between these 
syndromes and markers of skeletal muscle weakness. Finally, we propose potential areas for 
future research. 
Identification of literature 
Studies were identified through electronic searches of Medline, EMBASE and CINAHL for 
articles published from January 1966 to May 2016, using key search terms based on 
‘sarcopenia’ (muscle, sarco*, wasting), ‘frailty’ (frail*, geriatric) and ‘respiratory disease’ 
(COPD, fibrosis, lung disease, pulm* disease, respir*), modified according to the specific 
vocabulary of each database. Reference and citation lists of all identified articles were hand-
searched and authors in the topic area were contacted to identify additional studies. We 
limited the review to studies defining sarcopenia as a syndrome, in line with an international 
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consensus definition, and excluded studies where sarcopenia was defined on the basis of 
low muscularity or low fat free mass alone (see (22) for a recent review). 
Sarcopenia and frailty as Syndromes 
Sarcopenia 
Sarcopenia is a common condition with reported prevalence of 5–13% in those aged 60–
70 years, and as high as 50% for those aged 80 or above (23). In older people sarcopenia has 
been associated with a number of adverse outcomes including physical disability, poor 
quality of life, dependency in activities of daily living and excess mortality (24, 25).  The term 
is originally derived from the Greek words “sarx” and “penia” literally meaning “loss of 
flesh”, and classically sarcopenia has been defined as the “involuntary loss of muscle mass 
that occurs with advancing age” (26, 27). However, multiple genetic, lifestyle and 
environmental factors (e.g. smoking, physical inactivity, poor diet) have been shown to 
contribute and hasten the development of sarcopenia, irrespective of age (28, 29). With the 
exact aetiology of sarcopenia unknown, and knowledge of how these multiple factors 
interact lacking, a concrete definition of sarcopenia for use across clinical and research 
settings has been elusive. 
More recently there has been a move to understanding sarcopenia as a clinical ‘geriatric 
syndrome’ rather than simply as an age-related disease. A geriatric syndrome is a term used 
to describe common conditions, occurring as a result of impairments across multiple 
physiological systems, which ultimately lead to vulnerability, poor reserve and significant 
morbidity and mortality (9). Geriatric syndromes do not fit typical patterns of disease, but 
are manifest by a number of frequently observed characteristics (9). Sarcopenia fulfils the 
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definition of a geriatric syndrome on a number of counts.  It is without a doubt a common 
and complex medical condition, with multiple causative factors, and the potential for huge 
personal and financial cost (23). Sarcopenia is also characterised by progressive and 
generalised loss of skeletal muscle mass and strength, and crosses a number of diseases 
(24). To reflect this understanding, most consensus criteria require measurable markers of 
both low muscle mass and low muscle function (strength or performance) to be present for 
a sarcopenia diagnosis to be given (30). This view is supported by data demonstrating that 
loss of muscle mass does not always lead to further functional impairment (4, 31) and the 
relative lack of cut-points for weakness that relate to functional status (3).  
Frailty 
Frailty is a broader syndrome than sarcopenia that encompasses physical, social, cognitive 
and psychological domains. Frailty also develops as a result of multisystem age-related 
decline, which results in a gradual reduction in physiological reserve and increased 
vulnerability to sudden changes in health status which can be triggered by minor stressor 
events, e.g. a minor infection (12). The prevalence of frailty has been shown to increase 
non-linearly with adult age and is present in 10% of those over 65 years and a quarter of 
those older than 85 years (32). Frailty substantially increases the risk of falls, delirium, 
disability, institutionalisation, and death (33, 34). The prevalence of frailty is higher in 
women than men (35), but the relative mortality risk is lower in women than men (36). 
Agreeing an operational definition for frailty has also been controversial and in the current 
International Classification of Diseases (ICD), frailty is listed simply as a condition of ‘age-
related physical disability’ (ICD-10-R54).  Like sarcopenia, frailty can be considered a clinical 
geriatric syndrome; it is common and complex, has multiple causative factors, and spans 
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multiple disease states. From a landmark study in older people, Fried et al. demonstrated 
that a combination of unintentional weight loss, exhaustion, weakened grip strength, slow 
walking, and low physical activity, was associated with a mortality rate of 43% at seven 
years in those who were frail (defined as having at least three of these characteristics), 
compared to only 12% among those who were not frail (35). Shortly following this work, 
Rockwood et al. published on a clinical Frailty Index from the Canadian Study of Health and 
Aging, which quantified the presence or absence of 92 variables as a ratio (37). The index 
suggests that frailty is a result of the proportion of deficits or diseases accumulated with 
age, and that this increasing deficit characterises a person’s health status and determines 
their risk of future adverse events, including death (37, 38). An index of 0·67 (62/92 
variables) identified an amount of frailty beyond which further deficit accumulation was not 
sustainable and death was imminent (39). This model of frailty supports Fried’s concept of a 
reduced functional reserve, but is more explicit in the view that once a critical number of 
deficits have been amassed, any further insult will result in an adverse event. Here frailty 
can also be quantified, and the accumulated vulnerability measured, rather than 
dichotomised into the presence or absence of frailty as with the phenotypic models. 
Contextualising sarcopenia and frailty as syndromes has helped to develop practical ways to 
screen, identify and assess those at high risk of adverse outcomes. By assessing contributing 
factors, clinicians are also able to identify appropriate strategies to reduce risk in a 
personalised manner, aiming to prevent or delay the occurrence of disability, falls, 
dependency and even death. 
 
Assessment of sarcopenia and frailty  
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Sarcopenia 
Numerous national and international groups have reached consensus on the definition, 
assessment and diagnosis of sarcopenia.  There is now widespread agreement that 
sarcopenia should be defined as a combination of low muscle mass and loss of function, 
indeed a new ICD code (ICD-10-M62.84) recognizes sarcopenia as a separately reportable 
condition to muscle wasting or weakness alone, and age-related physical disability.  
Definitions typically include a measure of physical performance related to muscle loss, most 
often either weak hand grip strength or a slow gait speed (Table 1) (40, 41). 
Consensus on measurement standards or diagnostic cut-point is still lacking. Regarding 
assessment of muscle mass, different groups incorporate dual x-ray absorptiometry (DXA), 
bioelectrical impedance analysis (BIA), and/or computational tomography assessment into 
their diagnostic schemes (Table 1). The ease with which these measures can be applied is 
variable. Whilst DXA may offer a more accurate assessment of muscle mass than BIA (42), a 
disadvantage is that DXA is not widely available in clinical practice, particularly within 
settings where sarcopenia may be particularly relevant (nursing homes or critical care). To 
highlight this issue, the Foundation for the National Institutes of Health (FNIH) Sarcopenia 
Group required measures derived from DXA and in doing so had to exclude more than half 
of their validation dataset in whom measures were unavailable (43, 44). In contrast, the 
European Working Group on Sarcopenia in Older Persons (EWGSOP) criteria are more 
pragmatic and accept the use of BIA, a practical measure routinely used in our day-to-day 
practice (45), but this may overestimate muscle mass, particularly in overweight or obese 
patients, resulting in a ‘hidden’ population with undiagnosed sarcopenic-obesity.  
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The assessment of physical function commonly includes an objective measure of hand grip 
strength and/or gait speed, both of which have strong psychometric properties assuming 
there is sufficient operator training and standard testing procedures to reduce 
measurement error (46-48). Despite consistency in the type of assessment required, 
important variation exists in the cut-points used. For example, cut-points for grip strength in 
women range from 16 to 20kg and gait speed cut-points range from 0.8 to 1.0 
metres/second across the different tools (Table 1). As a result prevalence estimates for 
sarcopenia vary considerably, though where reported EWGSOP and FNIH criteria tend to 
share the highest levels of agreement (49-51). 
An alternative approach to sarcopenia assessment is seen in the SARC-F, a short 
questionnaire designed for clinical screening. It considers falls, stair climb and 
lifting/carrying as functional deficits related to muscle dysfunction but does not consider 
markers of muscle mass. The SARC-F has been validated against three consensus definitions 
of sarcopenia from Europe, United States and Asia (EWGSOP, IWSOP, AWGS, see Table 1) to 
predict 4-year physical limitation, walking speed and chair stand (52) and could be used to 
identify patients in whom a more comprehensive assessment is warranted. The assessment 
of functional deficit in this and other sarcopenia tools underscores the overlap between 
sarcopenia and frailty. Gait speed and grip strength are utilised in instruments across both 
syndromes, especially those focusing on physical manifestations of frailty (Table 1). 
Frailty 
As outlined above, two predominant models of frailty have emerged; the phenotype model 
(35) and the cumulative deficit model (38). The phenotype model developed by Fried et al. 
(35) focuses on physical frailty as being distinct from disability and comorbidity. Fried’s 
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model offers an objective measure that categorises people into three categories, frail, pre-
frail and robust. An alternative, but not conflicting, perspective it that frailty is the 
accumulation of physiological deficits across multiple organ systems (53). Rockwood et al’s 
Frailty Index typifies this approach by assessing frailty based on the number of deficits 
observed, each given equal weighting.  There is flexibility in how an index is derived, as long 
as there are over 40 variables that fulfil specified criteria (53). This approach to frailty 
assessment is more inclusive than the phenotype model as it considers multiple deficits 
across physical, cognitive, and illness related domains that are assessed through a 
comprehensive assessment. In contrast to the phenotype model, disability and comorbidity 
are here seen as integral components of frailty, which some view as a criticism since it is 
contended that frailty precedes disability (38). Other common instruments such as the 
Edmonton Frailty Scale (54) take an even broader view of frailty and include social support 
within an assessment (Table 1). Sternberg and colleagues examined the most common 
domains within frailty instruments and identified the top three as being physical function, 
mobility, and cognition (55). 
A recent systematic review found a total of 67 different frailty instruments, nine of which 
were had accumulated over 200 citations (56). Fried’s phenotype was the most widely used 
and cited, followed by the Frailty Index from Rockwood et al (38). Other common 
instruments include the Clinical Frailty Scale and the FRAIL scale, the use of which has 
increased dramatically in the last decade (56, 57). Frailty instruments vary widely in terms of 
the domains assessed, whether objective tests are included, and data sources. For instance, 
the FRAIL scale uses five self-report questions, whereas the Edmonton Scale (54) requires a 
drug review, tests of cognitive and physical function, plus assessments of Activities of Daily 
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Living (ADL) dependence, mood and general health. Frailty may be assessed in clinical 
practice, research, or in policy (56). Each instrument has its advantages and disadvantages 
(58) and the choice of an instrument should reflect the context and overall purpose of 
assessment. In clinical practice frailty assessment may guide decision-making around an 
approach to care, decision to undertake an investigation or procedure, or signposting to 
other services.  A nurse may consider the FRAIL scale to screen for frailty due to its ease and 
simplicity, or turn to the more holistic Edmonton Scale, which although more time 
consuming to complete may help them understand what is causing someone’s frailty to 
direct input from other services. In research frailty instruments have mostly been used to 
predict adverse outcome (56), but their role to determine eligibility for a study, or as a 
target for intervention should not be overlooked. In the case of a physical exercise 
intervention Fried’s model is well suited given its focus on physical frailty (20) whereas for 
more integrated approaches an global instrument from frailty may be more appropriate. 
Sarcopenia and Frailty in Chronic Respiratory Disease 
There are limited studies examining sarcopenia and frailty in chronic respiratory disease to 
date and a reliance on the stable disease setting, which is important to recognize given that 
exacerbations and/or hospitalisation will hasten deconditioning and likely increase 
sarcopenia and frailty states (1, 2). Only one study  has focused on sarcopenia (59), which 
found a 15% prevalence in people living with stable COPD (Table 2). Of those studies 
examining frailty prevalence, the overall interpretation is that frailty is increased in the 
presence of chronic respiratory disease. Only a single  retrospective study suggested frailty 
is not increased in respiratory disease and this concerned patients with very mild disease 
(mean (SD) FEV1 79.6 (25.2) % predicted)(17). Prevalence estimates vary considerably across 
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the studies, ranging from 5-65% for frailty and 22-64% for pre-frailty (Table 2). This variation 
is likely due to differences in both the criteria used and populations or settings studied. 
Frailty prevalence has been associated with a number of factors including physical inactivity, 
impairment due to breathlessness, poor respiratory function, and increasing comorbidity 
burden (17, 20, 21). When assessed cross-sectionally the combination of frailty and these 
factors has led to poorest outcomes, with evidence of a cumulative adverse effect (17, 60). 
Consistent with the literature in older people, studies demonstrate that frailty is associated 
with poor outcomes in chronic respiratory disease including increased falls, hospitalizations, 
and greater levels of disability (16, 19, 59, 61).  Prospective studies also support frailty as a 
predictor of mortality; often being frail at least doubles the risk of mortality, which has 
obvious implications for effective disease management (17, 60, 62) (Table 2). There are also 
examples of frailty adversely affecting patients’ odds of receiving disease modifying surgical 
(19) and non-pharmacological (20) treatments, which should equally be considered an 
important adverse outcome. 
Pulmonary rehabilitation has been shown to improve outcomes in both sarcopenic and frail 
patients. Improvements in symptom burden, physical function and overall health status 
have been demonstrated following a rehabilitation programme, and in some patients this 
led to a reversal and declassification of their sarcopenia and frailty status (20, 59, 61). The 
change in status partly reflects the working of phenotype models, as patients falling close to 
one or more cut-points only require a small improvement for their status to be changed. 
Nonetheless there is significant overlap between key characteristics of sarcopenia and frailty 
and common targets of rehabilitation, e.g. muscular strength, physical activity and vitality. 
The presence of sarcopenia does not appear to restrict patients from participating in 
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pulmonary rehabilitation (59), but the impairment associated with frailty does seem to 
hinder completion of a programme. Of those referred for rehabilitation in one study, being 
frail doubled a patient’s odds of programme non-completion (20).Although limited to one 
study, there is some evidence to suggest that the relationship between frailty and chronic 
respiratory disease could be bi-directional. Vaz Fragoso et al. observed that frailty was 
associated with increased odds of developing respiratory impairment, and conversely 
respiratory impairment was associated with increased odds of developing frailty (60). This 
finding needs to be confirmed, and perhaps extended to exacerbations of disease where 
respiratory impairment can persist (63), but could have important implications as strategies 
targeting one condition may be extend to both. 
Another interesting aspect linking frailty and chronic respiratory disease warranting further 
study is the role of inflammatory biomarkers (19). It is possible that cachectic COPD patients 
with persistent inflammation could be at particular risk for the development of frailty, and it 
is therefore important to better understand this potentially treatable biological mechanism. 
Relationships between skeletal muscle weakness, sarcopenia and frailty 
Two cohort studies arising from the Harefield Hospital Pulmonary Rehabilitation service (20, 
59) provide data to examine the relationships between skeletal muscle weakness, 
sarcopenia and frailty in more detail (see Table 2). Of 90 participants with COPD who were 
sarcopenic by EWGSOP criteria, 89% had hand grip weakness, 54% a slow gait speed, and 
48% both markers of reduced physical performance. An additional 27 participants from this 
study (4% of the overall sample) had low skeletal muscle index without either marker of 
reduced physical performance. In this sub-group group there was also no evidence of 
reduced global function or exercise capacity. This  supports the contemporary view of 
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sarcopenia requiring a degree of functional muscular impairment in that adding low physical 
performance to a sarcopenia diagnosis appears to further differentiate those with and 
without the syndrome. In a related but larger cohort, 209 participants were found to be frail 
by Fried’s phenotype criteria. Among this frail group the majority of patients  demonstrated  
hand grip weakness (80%) and  had a slow gait speed (72%) (20). These findings endorse the 
view that muscle dysfunction is an important contributor to sarcopenia and frailty in chronic 
respiratory disease. 
Another way to explore muscle dysfunction in relation to sarcopenia and frailty is to observe 
upper and lower limb muscle strength according to the presence of these syndromes. Mean 
(SD) hand grip strength values of 21.5 (7.5) kg and 21.3 (8.2) kg were found among 
sarcopenic and frail patients from the two studies respectively, compared with values of 
27.6 (10.0) and 33.0 (8.9) kg among other study participants. Whilst these values are in part  
a product of the diagnosis for sarcopenia or frailty, values for the lower limb (which are note 
considered in a diagnosis) revealed a similar pattern. Quadriceps maximum voluntary 
contraction values of  19.8 (7.6) kg and 21.0 (9.0) kg were found among sarcopenic and frail 
patients respectively, compared with 27.1 (10.2) kg and 31.0 (10.1) kg among those not 
sarcopenic or not frail in the two studies. The between groups differences of about 8-10kg 
are likely to be clinically significant but this needs to be confirmed. The ratios of upper:lower 
limb strength are also noteworthy, with mean hand grip values exceeding those for the 
quadriceps, which reflects the propensity of muscle dysfunction in COPD towards the lower 
limbs (1, 2). 
The relationships between sarcopenia, frailty and  quadriceps weakness, defined according 
to healthy predicted values (64),could be further explored in 707 participants with full 
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measurements. A complex interplay exists between quadriceps weakness, sarcopenia and 
frailty, which appear as overlapping but distinct clinical phenotypes (Figure 1). With the 
caveat that each phenotype depends on cut-points used (derived from observational 
studies), quadriceps weakness was the most common phenotype, observed in 57% of 
patients, followed by frailty, observed in  23%, and sarcopenia, observed in  12%. About 
two-thirds (64%) of those patients with quadriceps weakness did not exhibit concurrent 
sarcopenia or frailty, whereas only a minority of patients with frailty (16%) had neither 
quadriceps weakness nor sarcopenia. Just 3% of patients had all three phenotypes and we 
hypothesise this group carry the highest risk of adverse outcome (Figure 1). 
Future directions and opportunities 
Having reviewed current evidence around sarcopenia and frailty in chronic respiratory 
disease, future work may include; applying models to groups not represented in studies to 
date, e.g. restrictive diseases; comparing the prognostic utility of sarcopenia and frailty 
models against each other and multidimensional indices; optimising exercise-based 
treatments to manage these syndromes; and exploring additional strategies focused on 
nutrition, lifestyle factors, and pharmaceuticals. 
The evidence to date is biased towards studies of frailty rather than sarcopenia, phenotypic 
rather than cumulative deficit models of frailty, COPD rather than other chronic lung 
diseases, and stable rather than acute settings. Applying sarcopenia and frailty models 
across the range of diseases and settings will be necessary to fully understand these 
syndromes and their value to the field. Recent studies have assessed constructs closely 
related to sarcopenia and frailty in the acute setting, e.g. localised muscle wasting (65) and 
gait speed (18), and provide a strong basis on which examine validated models of 
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sarcopenia and frailty. Studies investigating the prognostic utility of sarcopenia and frailty 
have generally been retrospective and used modified frailty criteria that deviated from 
validated instruments. Again, new prospective validations based on this work should be 
undertaken to confirm these initial findings, adhering to the original instruments, and 
capturing outcomes using robust collection methods. Further, as studies have made use of 
existing datasets, the adverse outcomes collected are often limited to mortality alone, and 
the full range of outcomes common to geriatric syndromes has not been exploited. As well 
as tracking mortality studies should, where possible, assess incident falls, ADL disability, care 
home admission and hospitalisation. The comparative prognostic value of these syndromes, 
both in relation to each other and to leading prognostic indices, e.g. ADO and BODE, should 
also be tested if they are to compete as mainstream clinical markers. 
Future work should also address how sarcopenia and frailty can be optimally managed 
within respiratory disease. Exercise-based strategies can be used to reduce the impact of 
these syndromes on patients and the evidence suggests both and frailty can be reversed not 
just prevented, a notion supported by the gerontology literature (66). The holistic 
pulmonary rehabilitation model has proven to be highly effective at improving health status 
in respiratory disease. Many components of this model target sarcopenia and frailty related 
outcomes, e.g. falls prevention strategies. The ‘dose’ of rehabilitation delivered through the 
model also appears sufficient to change sarcopenia and frailty domains, which suggests a 
reduced risk of adverse events occurring, though this needs to be confirmed. Given the 
difficulty frail people experience completing a programme, further work is required to 
understand how better to support frail patients, perhaps via organisational changes, e.g. 
transport schemes or flexible class scheduling (67), or via supplementary training strategies, 
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e.g. muscle stimulation (68). The overarching goal would be for more people to access and 
benefit from a rehabilitation approach. 
Additional treatment strategies could include nutritional interventions and review of 
polypharmacy. Nutritional assessment should be an integral part of holistic disease 
management, but is often overlooked or not given sufficient attention (22). In some patients 
malnutrition may be a key driver of the sarcopenia and frailty syndromes and appropriate 
nutritional support may be paramount to bringing meaningful change. Finally, with 
increasing multi-morbidity more patients are prescribed multiple medicines. The 
introduction of a new drug can represents a stressor and the cumulative side effects and/or 
drug interactions can contribute directly to frailty (12). Tools to support evidence-based 
medication reviews and/or appropriate rationing are advocated for the care of older people 
(15, 69, 70). Conversely, the advent of medicines directed specifically at muscle (71) may 
change the treatment landscape and offer new prospects in sarcopenia and frailty 
management in chronic respiratory disease and beyond. 
 
Summary 
Sarcopenia and frailty are geriatric syndrome that are related to and reflected by markers of 
skeletal muscle dysfunction. Numerous instruments have been validated to help assess 
sarcopenia and frailty, and the choice of one over another depends on the context and 
primary purpose of assessment. Both sarcopenia and frailty are common in people with 
chronic respiratory disease and prevalence is positively associated with increasing age, 
disease severity, symptom and comorbidity burden. Frailty assessment can be used to 
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identify patients with chronic respiratory disease at increased risk of falls, hospitalizations, 
and mortality, in whom preventative interventions can be commenced. A complex interplay 
exists between quadriceps weakness, sarcopenia and frailty, which are overlapping but 
distinct clinical phenotypes. Suggested areas for future work include studies in the acute 
setting, the prospective prognostic assessment of sarcopenia and frailty models in relation 
to each other and to current multidimensional indices, as well as the continued 
investigation of exercise, nutritional and pharmacological strategies to help prevent or treat 
sarcopenia and frailty in chronic respiratory disease.
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Table 1: Assessment domains of common sarcopenia and frailty instruments 
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Sarcopenia               
Society for Sarcopenia, 
Cachexia and Wasting 
Disorders, Sarcopenia with 
limited mobility(15) 
Appendicul
ar lean 
mass index 
 
(>2 SD 
below 
mean) 
6MWT 
(<400m) 
or 
Gait speed 
(<1.0m/s) 
- - - - - - - - - - - - 
European Society for Clinical 
Nutrition and Metabolism 
(ESPEN) (72) 
Muscle 
mass (>2 SD 
below 
mean) 
4MGS 
(<0.8m/s) 
- - - - - - - - - - - - 
European Working Group on 
Sarcopenia in Older Persons 
(EWGSOP)(73) 
BIA skeletal 
muscle 
index (men 
<8.5 kg/m
2; 
women 
<5.75kg/m
2
) 
4MGS 
(<0.8m/s) 
Grip 
strength 
(men 
<30kg, 
women 
<20kg) 
- - - - - - - - - - - 
International Working Group 
Sarcopenia (IWGS) Task 
Force(74) 
Appendicul
ar lean 
mass index 
(men 
<7.23 kg/m
2
 women 
<5.67 
kg/m
2
) 
4MGS 
 (<1.0 m/s) 
- - - - - -  - - - - - 
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Asian Working group for 
Sarcopenia (AWGS)  (75, 76) 
DXA  (men 
7.0 kg/m2 
women 5.4 
kg/m2) 
Or BIA  
(men 7.0 
kg/m2 
women 5.7 
kg/m2) 
 
6MGS 
(<0.8m/s) 
Grip 
strength 
(men <26kg 
women 
<18kg) 
- - - - - - - - - - - 
Foundation for the National 
Institutes of Health (FNIH) 
Sarcopenia Project  (49) 
DXA 
appendicul
ar lean 
mass/ BMI 
(men 0.512 
women 
0.789) 
4/ 6 MGS 
(<0.8m/s) 
Grip 
strength 
(men <26kg 
women 
<16kg) 
- - - - - - - - - - - 
SARC-F (52)  - Assistance 
walking 
across a 
room 
Difficulty 
lifting and 
carrying 
10lb, 
difficulty 
climbing 10 
stairs 
- Falls 
(past year) 
- - - - Transfer 
from chair 
or bed 
- - - - 
Frailty               
Fried’s Frailty Phenotype(35) - 4MGS Grip 
strength 
Physical 
activity 
level 
- Self-
reported 
exhaustion 
Weight loss 
(>5% in last 
year) 
- - - - - - - 
FRAIL Scale (57) - Ability to 
walk 
several 
hundred 
yards 
Ability to 
climb a 
flight of 
stairs 
- - Tiredness Weight loss 
(>5% in last 
6 month) 
Illnesses 
(>5) 
- - - - - - 
CSHA Clinical Frailty Scale(38) - Mobility - Physical 
activity 
level 
- Tiredness - - Level of 
active 
symptoms 
Help with 
ADLs 
Dementia  - - - 
Frailty Index (77) (defined - Mobility, - - Falls  Tiredness - Illnesses - Help with Memory, Social Mood - 
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according to 70 deficits (38)) gait pattern ADLs cognition support 
E-Frailty Index (78) (defined 
according to 36 deficits) 
- Mobility, 
transfers 
- Activity 
limitation 
Falls - Weight 
loss, 
anorexia 
Presence 
of chronic 
conditions 
Symptoms 
including 
dyspnoea, 
dizziness 
Care 
Require-
ment  
Memory, 
cognition  
Social 
support, 
house-
bound 
- >5 drugs 
prescribed 
Tilburg Frailty Indicator(79)  - Walking Strength in 
hands 
Physical 
activity 
level 
- Tiredness 
(physical) 
Weight loss Physical 
health 
Balance, 
vision and 
hearing 
 Cognition Social 
support, 
relations, 
living status 
Depression, 
anxiety, 
coping 
 
Edmonton Scale (54) - Timed up 
and go test 
- - - - Weight loss 
(yes/ no) 
General 
health 
- Help with 
ADLs, 
continence 
Draw clock-
face task 
Social 
support 
Sadness, 
depression 
>5 drugs 
prescribed 
 
 
Legend: 6MWT = 6 minute walk time; 4MGS = 4 metre gait speed; DXA= dual x-ray absorptiometry; BIA= bioelectrical impedance analysis; ADLs= activities of daily living 
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Table 2. Studies of sarcopenia and frailty syndromes in chronic respiratory disease 
Reference Design Sample Key measures Main findings Implications 
Sarcopenia      
Jones et al. 2015 
(59) 
Cross-
sectional 
 
 
Case-control 
622 with COPD 
 
43 sarcopenic 
patients and 
43 propensity score-
matched controls pre-
post rehabilitation 
EWGSOP criteria 
ISWT 
QMVC 
CAT 
Physical activity by questionnaire 
and accelerometry 
Overall prevalence of sarcopenia 15%. Prevalence 
associated with age, breathlessness and disease 
severity. 
 
Sarcopenic patients had reduced exercise capacity, 
functional performance, physical activity and 
health status (p<0.001). 
 
Outcomes to pulmonary rehabilitation were similar 
across patients with sarcopenia and a propensity 
matched control group. 
 
Following rehabilitation 12/43 (28%) sarcopenic 
patients no longer met EWGSOP criteria. 
Sarcopenia is a distinct phenotype from 
generalised muscle wasting or physical 
function alone, and is associated with a 
worse functional and health status.  
 
Response to pulmonary rehabilitation 
is not impaired by sarcopenia and can 
lead to a reversal of the syndrome in 
some patients. 
Frailty      
Akgün et al. 2016 
(80) 
Prospective 
cohort 
7144 (3538 HIV 
positive) of whom: 
 
154 HIV positive with 
COPD 
182 HIV negative 
without COPD 
4-item adapted of Fried’s Frailty 
Phenotype  
 
Physical Limitation Scale 
 
Prevalence of frailty in patients with COPD 59% 
and 58% in those with HIV positive and negative 
status respectively. 
 
COPD was associated with increased odds of being 
frail (p<0.01) and with physical limitation 
(p<0.001). 
 
COPD associated with 5-fold greater odds of frailty 
in HIV positive group, and 3.5 fold grater odds in 
those with HIV negative status. 
Optimizing COPD management may be 
important to minimize frailty and 
maintain physical function for 
individuals aging with HIV. 
Valenza et al. 2016  
(81)  
Cross-
sectional 
 
212 with COPD 
(104 stable, 108 acute 
during exacerbation)  
 
100 without COPD  
Fried Frailty Phenotype 
Physical activity questionnaire 
Barthel Index 
Charlson Index 
Prevalence of frailty 63% in acute COPD and 65% in 
stable COPD. 
 
Cut-points to detect frailty using Baecke 
questionnaire 3.54 and 3.88 for acute and stable 
COPD. 
Measuring physical activity can help to 
predict the presence of frailty in acute 
and stable COPD.  
 
Interventions aimed at increasing 
physical activity may reduce or delay 
frailty. 
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Park et al. 2013 
(21) 
Cross-
sectional 
 
98 chronic bronchitis 
70 COPD 
43 chronic bronchitis 
& COPD 
9 item criteria of frailty (based on 
Tilburg Frailty Indicator) 
Physical activity by accelerometry 
Basic and instrumental ADLs 
Prevalence of frailty 58% and of pre-frailty 22%. 
 
Self-reported breathlessness was the strongest 
predictor for frailty (odds ratio 3.98 95% CI 1.79-
8.88, p<0.05). 
 
Frail patients had a greater number of disabilities 
and poorer outcomes including difficulties in ADLs. 
Highlights the importance of 
recognising  
 
Frailty is highly prevalent in COPD and 
may have implications for care.  
 
Knowledge of frailty determinants can 
help health care providers identify pre-
frail patients and provide preventative 
interventions to delay frailty onset. 
Mittal et al. 2016 
(16) 
Prospective 
cohort 
120 Chronic 
pulmonary disease 
(67 COPD) 
Fried Frailty Phenotype 
Physical activity questionnaire 
100 foot walk test 
Prevalence of frailty 18% and pre-frailty 64%. 
 
Frailty was associated with increased number of 
falls (p=0.018) and hospitalizations (p=0.011) in 
past year. 
 
Gait speed correlated with frailty status (r
2
=0.36, 
p<0.001) and decreased as frailty increased 
(p=0.001). 
Frailty could help predict falls and frail 
patients may benefit from a 
comprehensive geriatric assessment. 
 
Gait speed may help screen for frailty 
in chronic respiratory disease, but is 
only a single component of frailty. 
Galizia et al. 2010 
(62) 
Cross-
sectional with 
mortality 
follow up 
 
489 with COPD 
 
799 without COPD 
Frailty Staging System 
Basic ADLs 
Charlson Index 
 
Prevalence of frailty 49%. 
 
With increasing frailty stage, mortality at follow up 
(12 years) increased from 54% to 97% in patients 
with COPD (p<0.001). 
Clinical frailty stage offers prognostic 
information on long term mortality risk 
in people with COPD. 
Lahousse et al. 2015 
(17) 
Prospective 
cohort 
402 with COPD 
 
1,740 without COPD 
Fried Frailty Phenotype 
Spirometry 
Exacerbation history 
 
Prevalence of frailty 5% and pre-frailty 45% 
 
Those with COPD more than twice as likely to be 
frail (odds ratio 2.2, 95% CI 1.34-3.54, p=0.002). 
 
Prevalence of frailty in COPD associated with 
breathlessness, airflow limitation, and frequent 
exacerbations. 
 
Frailty was an important determinant of mortality 
in COPD (hazard ratio 4.03, 95% CI 1.22-13.30, 
p=0.022) along with lung function and comorbidity 
count. 
Increased prevalence of frailty with 
COPD related to breathlessness and 
exacerbation frequency. 
 
For patients with COPD, frailty appears 
to offer prognostic information on 
mortality risk. 
Vaz Fragoso et al. 2012 
(60) 
Prospective 
cohort  
3578 older persons 
 
(262 with COPD) 
Fried Frailty Phenotype 
Spirometry 
15 foot walk test 
Prevalence of frailty in patients with COPD 10% 
and pre-frailty 54%. 
 
Frailty and respiratory impairment 
increase mortality risk, especially when 
both are present. 
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 Frailty associated with increased airflow limitation 
(odds ratio 1.88, 95% CI 1.15 to 3.09), and 
restrictive lung function (odds ratio 3.05, 95% CI 
1.91 to 4.88). 
 
In those without respiratory impairment at 
baseline, frailty was associated with increased 
odds of developing respiratory impairment at 4 
years (odds ratio 1.42, 95% CI 1.11 to 1.82). In 
those not frail at baseline, those with respiratory 
impairment had increased odds of developing 
frailty at 3 years (odds ratio 1.58, 95% CI 1.17 to 
2.13). 
 
Greater mortality in those with frailty and 
respiratory impairment (2.5 fold increase in those 
with both compared to neither) during follow up. 
 
There may be a bidirectional 
relationship between frailty and 
respiratory impairment which could be 
important for therapy.  
 
Strategies targeting frailty- or 
respiratory-related impairment may 
extend to both conditions. 
Singer et al. 2015 
(19) 
Prospective 
cohort 
395 Lung transplant 
candidates 
Fried Frailty Phenotype 
SPPB 
6MWD 
Blood Biomarkers (IL-6, TNFR1, 
IGF-1, leptin) 
 
Prevalence of frailty based on Fried Frailty 
Phenotype 28%. Prevalence was not associated 
with low skeletal muscle index. 
 
Frailty was associated with higher levels of plasma 
IL-6 and TNFR1, and lower levels of IGF-1 and 
leptin. 
 
Frailty was associated with greater disability and 
twice the incidence of delisting or death before 
transplantation (27% vs. 13%, p=0.077). 
Frailty assessment could provide 
important morbidity and mortality risk 
information. 
 
Frailty assessment could be used to 
identify lung transplant candidates at 
increased risk of post-transplant 
disability or poorer outcomes. 
Mittal et al. 2015 
(61) 
Prospective 
cohort 
30 Chronic pulmonary 
disease (23 COPD) 
Fried Frailty Phenotype 
Physical activity questionnaire 
100 foot walk test 
Prevalence of frailty 17% and pre-frailty 61%. 
 
Patients with frailty had frequent falls and 
hospitalisations within the last year.  
 
Following pulmonary rehabilitation, gait speed was 
improved (mean 0.88 to 1.02 m/s, p<0.001) and 
3/5 (60%) previously frail patients were no longer 
met case criteria for frailty. 
Pulmonary rehabilitation may improve 
frailty specifically through an effect on 
gait speed in some patients, but this 
effect is not consistent. 
Maddocks et al. 2016 
(20) 
Prospective 
cohort 
816 COPD Fried Frailty Phenotype 
MRC dyspnoea score 
Physical activity questionnaire 
Prevalence of frailty 26% and pre-frailty 64%. 
Prevalence of frailty increased with age, GOLD 
stage, MRC score and comorbidity burden 
Frailty is an independent predictor for 
pulmonary rehabilitation non-
completion.  
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ISWT 
HADS 
CRQ 
CAT 
(p<0.001) 
 
Frailty associated with over twice the odds of 
pulmonary rehabilitation non-completion (odds 
ratio 2.20, 95% CI 1.39-3.46, p=0.001). 
 
Patients who were frail had better treatment 
outcomes following rehabilitation, including better 
responses in MRC score, exercise capacity, physical 
activity and health status (p<0.001).  
 
71/115 (62%) previously frail patients no longer 
met case criteria for frailty following pulmonary 
rehabilitation. 
 
This highlights the importance of 
understanding frailty in the 
management of COPD and should 
prompt exploration of new ways to 
support frail patients through 
rehabilitation. 
 
Legend: ADLs=Activities of Daily Living; CAT=COPD Assessment Test; CRQ=Chronic Respiratory Questionnaire; EWGSOP=European Working Group on Sarcopenia in Older People; GOLD=Global 
Initiative for Chronic Obstructive Lung Disease; HADS=Hospital Anxiety and Depression Scale; IGF-1=Insulin-like Growth Factor 1; IL-6=Interleukin 6; ISWT=Incremental Shuttle Walk Test; 
QMVC=Quadriceps Maximum Voluntary Contraction; SPPB=Short Physical Performance Battery; TNFR1=Tumor Necrosis Factor Receptor 1; 6MWD=6 Minute Walk Distance 
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Figure 1.  Relationships between frailty, sarcopenia and quadriceps weakness in patients 
with COPD derived from (20). Numbers represent patients with each phenotype (n=707). 
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